7 results on '"Darshi M Desai"'
Search Results
2. Poststroke Depression, An Underrated Clinical Dilemma: 2022
- Author
-
Aneeque Jamil, Denise Csendes, Sai Dheeraj Gutlapalli, Keerthana Prakash, Kiran Maee Swarnakari, Meena Bai, Mohana Priya Manoharan, Rabab Raja, Aditya Desai, Darshi M Desai, and Ana P Arcia Franchini
- Subjects
General Engineering - Published
- 2022
3. The Effects of Proton Pump Inhibitors in Acid Hypersecretion-Induced Vitamin B12 Deficiency: A Systematic Review (2022)
- Author
-
Kiran Maee Swarnakari, Meena Bai, Mohana Priya Manoharan, Rabab Raja, Aneeque Jamil, Denise Csendes, Sai Dheeraj Gutlapalli, Keerthana Prakash, Darshi M Desai, Aditya Desai, and Safeera Khan
- Subjects
General Engineering - Abstract
Gastroesophageal reflux disease (GERD) is the most common disease, for which proton pump inhibitors (PPIs) are a widely used class of drugs. Due to their efficacy and relative safety profile, PPIs are used chronically by GERD patients. Although it is a safe drug, particular attention focuses on the long-term adverse effects of PPI. The association with vitamin deficiencies has received additional focus since chronic PPI treatment increases the incidence of vitamin B12 deficiency, especially in the elderly. However, numerous studies regarding the establishment of an association between PPI and vitamin B12 status revealed conflicting results. In this systematic review, we systematically examined observational studies that focused on the impact of chronic PPI effects on vitamin B12 absorption and diagnostic biomarkers of vitamin B12 deficiency. Our review showed significant changes in diagnostic biomarkers of vitamin B12 status in long-term PPI users, including elevated homocysteine and methylmalonic acid (MMA) concentration levels defining cellular vitamin B12 deficiency. Although there is uncertainty regarding the exact mechanism, it supports the concept that long-term intake of PPI can have clinical implications for vitamins.
- Published
- 2022
4. Obesity and Coronary Artery Disease: An Updated Systematic Review 2022
- Author
-
Mohana Priya, Manoharan, Rabab, Raja, Aneeque, Jamil, Denise, Csendes, Sai Dheeraj, Gutlapalli, Keerthana, Prakash, Kiran Maee, Swarnakari, Meena, Bai, Darshi M, Desai, Aditya, Desai, and Sai Sri, Penumetcha
- Subjects
General Engineering - Abstract
The primary goal is to identify the pathogenesis of cardiovascular illnesses in obese patients. Articles were extracted using the MeSH search approach from PubMed and Google Scholar databases. Inclusion and exclusion criteria were used, and duplicates were eliminated. Eight publications were finally included in this research study after two authors independently completed the quality check appraisal. Seven observational studies and one narrative review were found in our search. The publications evaluated the risk of coronary artery disease in metabolically healthy obese people with that of unhealthy obese adults and evaluated the effects of adipose tissue-mediated inflammation. Additionally, they offered several explanations for the obesity problem. Studies have indicated that adipocytokines and their pro-inflammatory cytokines have significantly affected the development of cardiovascular disease in obese subjects. The relationship between metabolically unhealthy people with increased risk for coronary artery disease (CAD) is unclear. It has also been shown that metabolically healthy obese persons are still at risk for developing coronary artery disease (CAD), as explained in certain studies in which inflammation plays a vital role in obese people. There hasn't been much data on the advantages of being physically active in overweight people, but obese people have to change their lifestyle as a first measure.
- Published
- 2022
5. The Risk of Fatal Arrhythmias Associated With Sertraline in Patients With Post-myocardial Infarction Depression
- Author
-
Sai Dheeraj, Gutlapalli, Keerthana, Prakash, Kiran Maee, Swarnakari, Meena, Bai, Mohana Priya, Manoharan, Rabab, Raja, Aneeque, Jamil, Denise, Csendes, Aditya, Desai, Darshi M, Desai, and Michael, Alfonso
- Subjects
General Engineering - Abstract
Sertraline is a first-line antidepressant and the most commonly used in the treatment of selective serotonin reuptake inhibitor (SSRI) in major depression. It is preferred due to its central and peripheral actions on the serotonergic system in patients with mental health issues as well as cardiovascular disease, particularly post-myocardial infarction depression. Some of the feared adverse effects include QT prolongation, arrhythmias including Torsades de pointed, and sudden cardiac death, which are associated with older antidepressants and are rarely seen with SSRIs, including sertraline. We tried to understand the risks associated with sertraline use in cardiac patients. We reviewed all the relevant information from inception up to July 2022 regarding the risks of sertraline use in cardiovascular diseases, particularly with a focus on post-myocardial infarction depression, and gathered around 500 articles in our research and narrowed it down to 37 relevant articles. The database used was PubMed and the keywords used are sertraline, arrhythmia, major depression, post-myocardial infarction, and ventricular tachycardia. We carefully screened all relevant articles and found articles supporting and refuting the effects of sertraline in increasing cardiovascular morbidity and mortality. We concluded that there is a significant variability due to confounding factors affecting individual cases. Overall, sertraline has no increased risk in comparison with other antidepressants and a comparatively preferable safety profile to other SSRIs like citalopram in general cases. Any patient with a high risk of arrhythmias due to any etiology should receive a screening ECG before sertraline prescription for baseline QT interval and genotyping for any serotonin transporter/receptor variations. Patients should also be periodically monitored for drug-drug interactions while on therapy. We encourage further research, including randomized clinical trials and post-marketing surveillance regarding the use of sertraline in high-risk cases.
- Published
- 2022
6. Gastrointestinal Microbiota and Breast Cancer Chemotherapy Interactions: A Systematic Review
- Author
-
Denise Csendes, Sai Dheeraj Gutlapalli, Keerthana Prakash, Kiran Maee Swarnakari, Meena Bai, Mohana Priya Manoharan, Rabab Raja, Aneeque Jamil, Aditya Desai, Darshi M Desai, and Safeera Khan
- Subjects
General Engineering - Abstract
Breast cancer is the most common type of cancer in women besides basal cell and squamous cell skin cancer. The current systemic therapy guidelines for this heterogeneous disease are mainly based on the molecular subtypes. However, more research is required to improve rates of therapy resistance and prevent side effects. Previous studies have shown that the human gut microbiota may have an important role in carcinogenesis as well as therapy outcomes, but this factor has not yet been integrated into therapy protocols. This systematic review aims to analyze how response rates and side effect profiles of breast cancer systemic therapies may be affected by the gastrointestinal microbiota. A literature search was performed using multiple databases and keywords related to gastrointestinal microbiota, breast cancer, and anticancer drugs. Studies were excluded if they primarily focused on diseases other than breast cancer. Abstracts, reviews, meta-analyses, and animal experiments were also excluded. After screening, nine studies met all selection criteria and included a total of 566 participants. Most studies described the impact of the gut microbiota on therapy response, but a few additionally discussed chemotherapy side effects, probiotics, or antibiotics. In general, diversity and specific microbiota were linked to chemotherapy response as well as prognosis. Microbiota diversity was also predictive of side effects such as neurological symptoms, weight gain, and constipation. The diversity and composition of gastrointestinal microbiota may serve as biomarkers and provide pathways for the optimization of chemotherapy in breast cancer patients.
- Published
- 2022
7. Sudden Cardiac Arrest in Athletes: A Primary Level of Prevention
- Author
-
Keerthana Prakash, Kiran Maee Swarnakari, Meena Bai, Mohana Priya Manoharan, Rabab Raja, Aneeque Jamil, Denise Csendes, Sai Dheeraj Gutlapalli, Aditya Desai, Darshi M Desai, and Pousette Hamid
- Subjects
General Engineering - Abstract
Primary prevention of sudden cardiac arrest (SCA) refers to the use of pharmacological or interventional therapy and healthy lifestyle modifications to prevent sudden cardiac death (SCD) in patients who have not experienced symptomatic, life-threatening persistent ventricular tachycardia or ventricular fibrillation or SCA but are considered to be at a higher risk. This review provides an overview of the physiological heart changes and distinct electrical manifestations, the etiology of SCA, and screening methods and interventions for the prevention of SCA in athletes. The American College of Cardiology and the American Heart Association (AHA) Guidelines recommend screening with a 14-point history and physical examination. In most cases, a thorough clinical evaluation along with an ECG is sufficient for screening. Athletes with heart diseases leading to SCD are urged not to compete. Further decisions are taken following the European Society of Cardiology and the AHA's current workout recommendations. Early detection of cardiac disease allows for individualized risk evaluation and treatment, which has been shown to reduce mortality rates in athletes.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.